GLP-1 microdosing: what to expect in your first 2-4 doses

Most GLP-1 side-effect guides describe the standard weight-loss ramp: semaglutide climbing from 0.25 mg to 2.0 mg over about four months, one step up every four weeks, with nausea baked into the plan. Microdosing runs a different protocol entirely, a fraction of that starting dose, held rather than escalated, and almost nobody self-prescribing it has a resource that says what the first two to four doses should actually feel like. So people import the standard-ramp nausea narrative onto a regimen that isn't built to produce it, and either panic at nothing or miss a real warning sign because they were braced for the wrong one.

What "microdose" actually means, in numbers

A clinical reference protocol used for GLP-1 dose planning puts the standard ramp at semaglutide 0.25 to 0.5 to 1.0 to 1.5 to 2.0 mg weekly, moving up roughly every four weeks. The microdose (longevity-track) range sits well under that: semaglutide 0.1 to 0.25 mg weekly (occasionally to 0.5 mg), tirzepatide 0.5 to 2.5 mg weekly, retatrutide roughly 0.25 to 0.5 mg weekly. Retatrutide's low-dose numbers are extrapolated from higher-dose trial data, not validated in humans at that range, so treat that one as investigational, not established.

Brand pens can't dose that low. A 0.25 mg semaglutide pen has no lower setting, which is why microdosing is typically drawn with an insulin syringe as a fraction of that starting dose. That's a real skill gap stacked on top of the clinical judgment gap: get the reconstitution or the draw wrong and the "microdose" isn't actually micro anymore.

Dose 1: what actually happens

At true microdose range, the honest answer is: not much, and that's the design, not a failure. Dr. Tyna Moore, the most visible clinical advocate for this approach, describes the target as dosing to "just below symptoms": no nausea, no vomiting, and if either shows up, her framework calls for backing the dose down, not pushing through it. That's the opposite of the standard-ramp mentality, where mild GI upset is expected and tolerated because the dose is climbing toward a therapeutic target.

What is normal on dose 1, even at the low end: a noticeable drop in appetite. Clinical microdose ranges flag that even a low dose suppresses appetite in otherwise lean, healthy users, enough that protein intake needs active protection from the first week, not after several doses. Mild injection-site stinging or a small bruise is also normal, roughly the range of a flu shot, and it improves with technique.

Doses 2-4: what's supposed to change (and what isn't)

Here's the part self-prescribers get backwards most often. The standard therapeutic ramp escalates on a schedule, a new higher dose roughly every four weeks, because the goal is to reach an effective weight-loss dose. Microdosing, per both the clinical reference range and Moore's framework, is designed to hold, not climb: find the dose that sits just under symptoms and stay there, rather than treating week 2, 3, and 4 as automatic step-ups.

A common pattern behind bad outcomes: impatience. Users who don't see a fast enough appetite or weight effect escalate faster than the protocol calls for. At true microdose range that impatience defeats the entire premise, since the design goal is a small, sustained nudge, not a compressed version of the weight-loss ramp.

Whether to space doses out further over time, weekly to every two weeks to monthly, to let receptors resensitize, is a genuinely unsettled question. Moore treats GLP-1 microdosing like a hormone that benefits from cycling; the standard-of-care view is that GLP-1s don't need cycling at all. That's a live disagreement between a clinical opinion and the conventional protocol, not a solved question you can look up.

Signals that mean back off, not push through

Nausea or vomiting at microdose range isn't a "push through it" situation the way it sometimes is on the standard ramp. It means either the dose landed higher than intended (check the reconstitution and the draw first) or the product isn't what the label says. Both are common enough to name specifically: one documented case involved someone injecting roughly 1 mg from an unregulated pen, well above even a standard starting dose, and getting severe vomiting from what amounted to a titration-skip. Separately, a widely circulated case involved a user who believed they were injecting retatrutide and were actually injecting Melanotan II, discovered only because their skin started darkening. Neither of those is a "your body adjusting" story. Verify what's actually in the vial before dose 1, not after a bad reaction, the same scrutiny that applies to any peptide source applies here. See how to vet a peptide seller before you draw the first dose.

Why nobody writes this down

The framework most associated with GLP-1 microdosing is explicit that this isn't a solo project: the stated position is not to buy GLP-1s online and self-dose at home, and the credentialed path described is a clinician with compounding-pharmacy access who can prepare true sub-0.25 mg doses and monitor the response. Most people reading a "first doses" guide are, by definition, running this without that setup, which is exactly why standard GLP-1 content (written for the clinic-supervised therapeutic ramp) doesn't map to what they're actually doing. That gap, not a lack of general GLP-1 information, is the real hole.

If week 4 brings a different symptom pattern than dose 1 did, that's a distinct question. See GLP-1 microdosing anxiety and sleep disruption at week 4 for that stage specifically. If you're starting standard-dose GLP-1 treatment rather than microdosing, the counseling gaps are different too, covered in first-time GLP-1 counseling checklist. More grounded breakdowns like this one are on the Ouros Lab blog.

FAQ

Is GLP-1 microdosing the same as the standard weight-loss ramp, just smaller numbers?

No. The standard ramp escalates on a fixed schedule toward a therapeutic weight-loss dose. Microdosing, per the clinical range and the Moore framework both, is designed to find a low dose and hold it, not climb it.

What's a normal reaction to a first GLP-1 microdose?

A noticeable drop in appetite, and possibly mild, short-lived injection-site stinging or bruising similar to a flu shot. Nausea or vomiting is not the expected baseline at true microdose range; it's a signal to check the dose and the source.

Can I microdose GLP-1s without a clinician involved?

The framework most associated with this approach explicitly advises against buying online and self-dosing at home. The described path is a clinician with compounding-pharmacy access who can prepare accurate sub-0.25 mg doses and monitor the response over time.

Should I space out doses over time instead of dosing weekly?

That's unsettled. Some clinicians treat GLP-1 microdosing like a hormone that benefits from cycling (weekly to biweekly to monthly); the conventional view is that GLP-1s don't need cycling at all. This is a live disagreement, not a resolved protocol, and it's a decision to make with a clinician who can track the response.